Trevi Therapeutics, Inc.TRVI
Price (close)
$14.68
Market cap
$2.1B
P/E
—
Revenue (TTM)
—
Net income
-$51.1M
Dividend yield
—
1-year total return
73.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Trevi Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$32.8M | -$33.9M | -$29.2M | -$29.1M | -$47.9M | -$42.8M |
| Free cash flow | -$29.0M | — | -$28.3M | -$31.8M | -$38.3M | -$42.1M |
More on TRVI.
- Trevi Therapeutics, Inc. summary
- Trevi Therapeutics, Inc. financial statements
- Trevi Therapeutics, Inc. key metrics
- Trevi Therapeutics, Inc. health scores and style box
- Trevi Therapeutics, Inc. earnings
- Trevi Therapeutics, Inc. dividends
- Trevi Therapeutics, Inc. valuation
- Trevi Therapeutics, Inc. ownership and insiders
- Trevi Therapeutics, Inc. peers
Figures from Trevi Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.